GET DAILY SIGNALSAcrivon Therapeutics (ACRV) Retreats -15.5% Over 30 Days: Clinical Readouts Still in Focus
Key Takeaways
- Acrivon Therapeutics (ACRV) shares declined roughly 15.5% over the last 30 days, falling from a closing price near $2.06 to about $1.74.
- The pullback largely unwound a sharp mid-August rally, with the stock still trading above its early-August level near $1.56.
- Acrivon is a clinical-stage precision oncology company advancing its lead candidate ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study in endometrial cancer.
- The near-term move reflected profit-taking and broader pressure on small-cap biotechnology names rather than a single company-specific announcement.
- Investor attention remains focused on the prespecified interim analysis of the ACR-368 serous endometrial cancer arms expected in the second half of 2026.
- As of June 30, 2026, Acrivon reported $90.0 million in cash, cash equivalents, and investments, with runway projected into the fourth quarter of 2027.
Company Background and Pipeline Focus
Acrivon Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on discovering and developing precision oncology medicines. The company's approach is built around its proprietary Generative Phosphoproteomics platform, known as AP3 (Acrivon Predictive Precision Proteomics), which measures drug-regulated pathway activity inside intact cells to guide drug design and identify patients most likely to respond to treatment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Acrivon's lead program, ACR-368 (also known as prexasertib), is a selective CHK1/CHK2 inhibitor being evaluated in a registrational-intent Phase 2b study for patients with recurrent, high-grade endometrial cancer. The FDA has granted Fast Track designation for ACR-368 in endometrial cancer, and the companion ACR-368 OncoSignature assay has received Breakthrough Device designation. The company's second clinical-stage asset, ACR-2316, is a WEE1/PKMYT1 inhibitor in Phase 1/2 development, and it is advancing ACR-6840, an internally discovered CDK11 inhibitor, toward an IND filing. Investors follow ACRV primarily for its clinical data catalysts and the potential of its AP3-enabled pipeline in areas of high unmet need.
Stock Price Moves: 30-Day Decline and Quarterly Context
Over the last 30 days, ACRV declined from a closing level near $2.06 to approximately $1.74, a move of about -15.5%. The decline was gradual rather than a single-session shock, with the stock drifting lower through October and giving back much of the gains accumulated earlier in the period.
The broader quarterly picture is more nuanced. Early in the quarter, the stock traded near $1.56 before rallying sharply to a peak above $2.39 in mid-August, a gain of more than 50% from its starting point. Shares then consolidated in a range between roughly $1.95 and $2.20 through much of September before softening into October. Measured from the start of the quarter, the stock remains modestly higher, up roughly 11%, but it now sits about 27% below its August peak, reflecting a classic round-trip in a volatile clinical-stage biotech.
Drivers Behind the Recent 30-Day Pullback
The 30-day decline was not tied to a single company-specific announcement. Instead, the move appears to reflect a normalization of the strong rally that followed Acrivon's August business updates, combined with profit-taking and broader pressure on small-cap biotechnology equities. Clinical-stage biotech names without near-term revenue can experience outsized swings when sentiment toward the sector shifts, and ACRV's low trading volume amplifies day-to-day price movement. From what I see, this pattern is fairly typical in the space right now.
Within the period, the stock staged a brief recovery in mid-to-late September before weakening again in October. The absence of fresh clinical data during the window left the stock to trade on technical factors and market sentiment. Investors continued to position ahead of the anticipated prespecified interim analysis for the ACR-368 Phase 2b serous endometrial cancer arms, a catalyst scheduled for the second half of 2026 that has kept the stock sensitive to shifting expectations about the timing and content of the readout.
Quarterly Performance Shaped by Pipeline Updates
Acrivon's quarterly move was shaped primarily by clinical and pipeline momentum. In early August, the company reported favorable safety and durable single-agent activity for ACR-2316, including heavily pretreated lung cancer patients remaining on treatment for over a year, and confirmed that ACR-2316 had advanced into the randomized dose-expansion stage of its Phase 1/2 study. In mid-August, alongside its second-quarter 2026 financial results, management reiterated that the prespecified interim analysis of the ACR-368 serous endometrial cancer arms remained on track for the second half of 2026 and that dosing continued across both arms in the U.S. and Europe.
These updates drove the stock's mid-August spike. As the initial enthusiasm faded and no major data readout arrived, shares gave back gains, a pattern common among development-stage oncology companies where valuation is heavily tied to binary clinical events. The quarterly trend therefore reflects a market that rewarded positive program progress but then de-risked into the data catalyst.
Key Catalysts Ahead for ACRV Investors
The most important near-term catalyst for ACRV is the prespecified simultaneous interim analysis of the ACR-368 Phase 2b study's all-comer serous endometrial cancer arms, expected in the second half of 2026. Management has also guided toward completing enrollment of the registrational-intent Arm 3 or Arm 4 by the fourth quarter of 2026, depending on the interim readout, with plans to initiate a Phase 3 confirmatory trial in the first half of 2027.
Beyond ACR-368, investors should monitor additional ACR-2316 dose-expansion data, the planned IND filing for the ACR-6840 CDK11 inhibitor, and any updates on AP3-driven discovery programs. Financial durability remains a key factor as well: with $90.0 million in cash reported as of June 30, 2026 and runway into the fourth quarter of 2027, capital-raising activity and spending discipline will influence sentiment. As with any clinical-stage biotech, the stock remains exposed to trial outcomes, regulatory decisions, and broader sector risk. I’m watching this closely as the data timeline approaches.
Using AI Tools for Biotech Analysis
In my view, automated strategies can add discipline when following volatile clinical-stage names like ACRV. I’ve used Tickeron’s AI Trading Bots to test different approaches on similar tickers, reviewing performance metrics and risk settings before applying anything to my own watchlist. The platform offers a range of options that align with varying timeframes and objectives, which helps when clinical catalysts create sharp moves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACRV's RSI Oscillator climbs out of oversold territory
The RSI Indicator for ACRV moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 25 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 56 cases where ACRV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on ACRV as a result. In 63 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for ACRV just turned positive on October 28, 2026. Looking at past instances where ACRV's MACD turned positive, the stock continued to rise in 28 of 34 cases over the following month. The odds of a continued upward trend are 82%.
Following a +4.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
ACRV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACRV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ACRV entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.885) is normal, around the industry mean (3.151). P/E Ratio (-0.952) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. ACRV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement